Long‐term follow‐up of noninvasive bladder tumours(stage Ta): recurrence and progression

Zieger, Karsten; Wolf, Hans; Olsen, Preben; Højgaard, Knud

doi:10.1046/j.1464-410x.2000.00547.x

Cited by 75 publications

(35 citation statements)

References 18 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Until now, risk tables for predicting recurrence have distinguished between two tumour size categories, <3 and ‡3 cm [1][2][3], whereas the present data indicate that another cut-off level of 15 mm may give additional valuable information. Other researchers investigating risk factors for recurrence and progression used identical strategies (<3 and ‡3 cm) for differentiation of tumour size [4,5]. However, the method of measuring the tumour size was not described in those publications.…”

Section: Discussionmentioning

confidence: 99%

“…Recurrence and progression in superficial bladder cancer are associated with several statistically established risk factors, including multiplicity, prior recurrence rate, T category, presence of concomitant carcinoma in situ (CIS), and tumour grade and size [1][2][3][4][5]. Tumours are generally divided into two size categories with a cut off of 3 cm.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder

Jancke¹,

Rosell

Jahnson³

2011

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder

Jancke¹,

Rosell

Jahnson³

2011

Scandinavian Journal of Urology and Nephrology

View full text Add to dashboard Cite

show abstract

“…Many of transitional cell carcinoma (TCC) cases are superficial, low-grade, non-invasive papillary tumours and may be treated with endoscopic resection. However, the recurrence rate is high for tumours treated with resection alone [2]. Therefore, patients with superficial bladder cancers are treated with resection, followed by prophylactic treatment with intravesical agents.…”

mentioning

confidence: 99%

Fisetin, a Dietary Flavonoid, Induces Cell Cycle Arrest and Apoptosis through Activation of p53 and Inhibition of NF‐Kappa B Pathways in Bladder Cancer Cells

Cheng

et al. 2010

Basic Clin Pharma Tox

104

View full text Add to dashboard Cite

There is an obvious urgent need to find effective and safe therapies to prevent both recurrence and progression of bladder cancer. In the present study, we report that fisetin-induced apoptosis in human bladder cancer is mediated via modulation of two related pathways: up-regulation of p53 and down-regulation of NF-kappa B activity, causing a change in the ratio of pro-and anti-apoptotic proteins. The results showed that fisetin inhibited the proliferation of T24 and EJ cells by inducing apoptosis and blocking cell cycle progression in the G0 ⁄ G1 phase. Western blot assay showed that fisetin significantly increases the expression of p53 and p21 proteins, and decreases the levels of cyclin D1, cyclin A, CDK4 and CDK2, thereby contributing to cell cycle arrest. In addition, fisetin increased the expression of Bax and Bak but decreased the levels of Bcl-2 and Bcl-xL and subsequently triggered mitochondrial apoptotic pathway. Our study suggests that the activation of p53 and inhibition of the NF-kappa B system may play important roles in the fisetin-induced apoptosis in bladder cancer cells.

show abstract

“…These tumors have a high frequency of recurrence (Ͼ60%), and about 10 -15% of them will progress to life-threatening malignancies (7,8). Currently, it is not possible to assess with certainty the biological behavior of these tumors based on clinical or morphological criteria alone, and as a result it is urgent to identify early and accurate biomarkers that may predict recurrence, progression, and response to treatment.…”

mentioning

confidence: 99%

Proteomic Strategies to Reveal Tumor Heterogeneity among Urothelial Papillomas

Celis

Pálsdóttir

et al. 2002

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Proteomics and immunohistochemistry were used to reveal tumor heterogeneity among urothelial papillomas (UPs) with the long term goal of predicting their biological potential in terms of outcome. First, we identified proteins that were deregulated in invasive fresh lesions as compared with normal urothelium, and thereafter we immunostained UPs with a panel of antibodies against some of the markers. Twenty-two major proteins showing variations of 2-fold or more in at least one-third of the invasive lesions were selected. Specific antibodies against several of the proteins were obtained, but only a few reacted positively in immunostaining. A panel consisting of antibodies against keratinocytes (CKs) 5, 13, 18, and 20 and markers of squamous metaplasia (CKs 7, 8, and 14) was used to probe normal urothelium and 30 UPs collected during a period of five years. Four UPs showed a normal phenotype, whereas the rest could be grouped in five major types that shared aberrant staining with the CK20 antibody. Type 1 heterogeneity (n ‫؍‬ 4) showed preferred staining of the umbrella cells with the CK8 antibody. Type 2 (n ‫؍‬ 11) was typified by the staining of the basal and intermediate layers with the CK20 antibody. Type 3 (n ‫؍‬ 7) was characterized by the predominant staining of the basal cell layer with the CK5 antibody. Type 4 (n ‫؍‬ 1) showed areas of CK7 negative cells, whereas type 5 (n ‫؍‬ 3) showed loss of staining of the basal cells with the CK20. 29% of the patients experienced recurrences, but none progressed to invasive disease. Patients harboring phenotypic alterations in the basal cell compartment (types 3 and 5) showed the highest number of recurrences (4/7 and 2/3, respectively), and all type 3 lesions progressed to a higher degree of dedifferentiation. Even though a long term prospective study involving a larger sample size is required to assess the biological potential of these lesions, we believe that this approach will prove instrumental for revealing early phenotypic changes in different types of cancer. Molecular & Cellular Proteomics 1:269 -279, 2002.

show abstract

Long‐term follow‐up of noninvasive bladder tumours(stage Ta): recurrence and progression

Cited by 75 publications

References 18 publications

Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder

Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder

Fisetin, a Dietary Flavonoid, Induces Cell Cycle Arrest and Apoptosis through Activation of p53 and Inhibition of NF‐Kappa B Pathways in Bladder Cancer Cells

Proteomic Strategies to Reveal Tumor Heterogeneity among Urothelial Papillomas

Contact Info

Product

Resources

About